

Non-Renounceable Rights Issue Acceptances and Shortfall

4 May 2009, Melbourne, Australia: Benitec Limited (ASX: BLT) advises that it has received acceptances and applications in respect of the following shares and free attaching options:

	Shares	Options	\$*
Acceptances of Entitlements	33,360,432	33,360,432	1,000,813
Acceptances of shortfall	2,179,122	2,179,122	65,374
Total	35,539,554	35,539,554	\$1,086,187

**before the costs of the offer.*

The Directors reserve the right to place the remaining shortfall of 64,460,446 shares and 64,460,446 free attaching options in accordance with the Prospectus.

The Directors consider this an excellent result in light of the current state of the financial markets and the difficulties being experienced by the global biotechnology industry. They expressed their thanks to shareholders for this show of support.

Holding statements for the new securities will be dispatched by 7 May 2009 in accordance with the timetable in the prospectus.

John Rawling
Company Secretary

CONTACTS:

BENITEC LTD
Sue MacLeman
Chief Executive Officer
+61 437 211 200

John Rawling
Company Secretary
+61 417 524 236

About Benitec

Benitec is an Australian biotechnology company focused on licensing its extensive intellectual property portfolio and developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. Its current therapeutic program is focused on Human Immunodeficiency Virus (HIV). For additional information, please visit www.benitec.com.